Novavax | PharmaTimes

Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine

Emily Kimber — Tue, 22 Apr 2025 11:21:42 +0000

The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine

John Pinching — Fri, 07 Jul 2023 11:34:00 +0000

Second dose of treatment generates response among young people during Oxford University trial

Lucy Parsons — Fri, 17 Sep 2021 11:25:00 +0000

The Phase II clinical trial will include at least 360 adolescents aged 12-16 years old

Lucy Parsons — Thu, 09 Sep 2021 10:30:00 +0000

The trial will aim to enrol 640 healthy adults, aged 50- to 70-years-old

Lucy Parsons — Wed, 16 Jun 2021 09:40:00 +0000

Study co-administered Novavax's COVID-19 vaccine alongside Seqirus' flu vaccines

Lucy Parsons — Tue, 15 Jun 2021 09:34:00 +0000

Jab was also found to be 100% effective at preventing moderate to severe COVID-19

Lucy Parsons — Wed, 14 Apr 2021 10:02:00 +0000

Trial will now include vaccines developed by Moderna and Novavax

Lucy Parsons — Tue, 30 Mar 2021 10:03:00 +0000

British drugmaker will help to produce up to 60 million doses for use in the UK

Lucy Parsons — Mon, 15 Mar 2021 10:01:00 +0000

Vaccine found to have an overall vaccine efficacy of 89.7% in Phase III trial

Lucy Parsons — Fri, 05 Feb 2021 09:51:00 +0000

Jab recently demonstrated 89.3% efficacy in UK trial